IMR Press / FBL / Volume 24 / Issue 1 / DOI: 10.2741/4710

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Co-signaling receptors regulate T-cell plasticity and immune tolerance
Show Less
1 Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China
2 Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China
3 Centers for Metabolic Disease Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, U.S.A
4 Cardiovascular Research, and Thrombosis Research
5 Department of Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, U.S.A
6 Department of Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, U.S.A
7 Department of Pathology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, U.S.A
8 Department of Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, U.S.A
9 Department of Biomedical Engineering, Duke University, Durham, NC, 27708, U.S.A.
10 Department of Cardiovascular Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming of Yunnan
Send correspondence to: Na Wu, Departmentof Endocrinology, Shengjing Hospital of ChinaMedical University, Shenyang, Liaoning,110004, China, Tel: 86 1894025610, Fax:8618940256156, E-mail: 176818815@qq.com
Front. Biosci. (Landmark Ed) 2019, 24(1), 94–128; https://doi.org/10.2741/4710
Published: 1 January 2019
(This article belongs to the Special Issue Regulation of vascular inflammation in atherosclerosis and diabetes)
Abstract

We took an experimental database mining analysis to determine the expression of 28 co-signaling receptors in 32 human tissues in physiological/pathological conditions. We made the following significant findings: 1) co-signaling receptors are differentially expressed in tissues; 2) heart, trachea, kidney, mammary gland and muscle express co-signaling receptors that mediate CD4+T cell functions such as priming, differentiation, effector, and memory; 3) urinary tumor, germ cell tumor, leukemia and chondrosarcoma express high levels of co-signaling receptors for T cell activation; 4) expression of inflammasome components are correlated with the expression of co-signaling receptors; 5) CD40, SLAM, CD80 are differentially expressed in leukocytes from patients with trauma, bacterial infections, polarized macrophages and in activated endothelial cells; 6) forward and reverse signaling of 50% co-inhibition receptors are upregulated in endothelial cells during inflammation; and 7) STAT1 deficiency in T cells upregulates MHC class II and co-stimulation receptors. Our results have provided novel insights into co-signaling receptors as physiological regulators and potentiate identification of new therapeutic targets for the treatment of sterile inflammatory disorders.

Keywords
co-stimulation and co-inhibition receptors
antigen presenting cells
reverse signaling
T cell plasticity
STAT1 deficiency
Figures
Figure 1
Share
Back to top